Five Zinc Finger Protein 350 Single Nucleotide Polymorphisms and the Risks of Breast Cancer: a Meta-analysis

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Jan 2

PMID 29291027

Citations 6

Authors

Yu Fan Zeng

Jianfeng Sang

Affiliations

Soon will be listed here.

Abstract

Some studies have reported an association between the zinc-finger protein 350 (ZNF350), also known as zinc-finger and BRCA1-interacting protein with a Kruppel-associated box (KRAB) domain (ZBRK1), and risks of breast cancer, although the results remain controversial. A systematic search was conducted on PubMed, Web of Science, EMBASE, Ovid, Chinese National Knowledge Databases, and WanFang databases with relevant keywords. Four studies of five distinct populations involving 5824 breast cancer cases were used to conduct a meta-analysis that summarizes the current evidence of 5 genetic polymorphisms: Asp35Asp, Leu66Pro, Pro373Pro, Ser472Pro, and Ser501Arg in the ZNF350 gene. The T allele in Asp35Asp polymorphisms not significantly associated with increased risk of breast cancer (OR: 1.08; 95% CI: 0.96-1.21). The minor C allele of the Asp35Asp polymorphism is protective in the overdominant model (OR = 1.14; 95% CI: 1.02-1.28). The Pro allele in the Leu66Pro polymorphism is protective in all of the models examined (allelic, dominant, recessive, and overdominant). The Pro373Pro is not associated with breast cancer in all of the models tested. The Pro allele of the Ser472Pro polymorphism is protective using the dominant model (OR = 0.10; 95% CI: 0.04-0.23) but deleterious using the overdominant model (OR = 1.14; 95% CI: 1.02-1.28). The Ser501Arg polymorphism is deleterious only when using the recessive model (OR = 1.21; 95% CI: 1.02-1.44). In conclusion, this meta-analysis suggests that genetic polymorphisms in the variant can increase, decrease, or have no effect on the risks of breast cancer depending on the polymorphism and genetic model used. Further studies will be required to validate these findings.

Citing Articles

miR-22-3p/PGC1 Suppresses Breast Cancer Cell Tumorigenesis via PPAR.

Wang X, Yao Z, Fang L PPAR Res. 2021; 2021:6661828.

PMID: 33777130 PMC: 7981180. DOI: 10.1155/2021/6661828.

Correlation between ZBRK1/ZNF350 gene polymorphism and breast cancer.

Wu J, Eni A, Roussuri E, Ma B BMC Med Genomics. 2021; 14(1):7.

PMID: 33407485 PMC: 7788962. DOI: 10.1186/s12920-020-00862-2.

An Innovative Platform Merging Elemental Analysis and Ftir Imaging for Breast Tissue Analysis.

Ali M, Rakib F, Al-Saad K, Al-Saady R, Goormaghtigh E Sci Rep. 2019; 9(1):9854.

PMID: 31285452 PMC: 6614471. DOI: 10.1038/s41598-019-46056-4.

The rs1126616 Single Nucleotide Polymorphism of the Osteopontin Gene Is Independently Associated with Cardiovascular Events in a Chronic Kidney Disease Cohort.

Cambray S, Galimudi R, Bozic M, Bermudez-Lopez M, Rodriguez I, Valdivielso J J Clin Med. 2019; 8(5).

PMID: 31036794 PMC: 6571716. DOI: 10.3390/jcm8050592.

PGC-1β cooperating with FOXA2 inhibits proliferation and migration of breast cancer cells.

Cao J, Wang X, Wang D, Ma R, Li X, Feng H Cancer Cell Int. 2019; 19:93.

PMID: 31007610 PMC: 6458718. DOI: 10.1186/s12935-019-0810-5.

References

WOOLF B . On estimating the relation between blood group and disease. Ann Hum Genet. 1955; 19(4):251-3. DOI: 10.1111/j.1469-1809.1955.tb01348.x. View

Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D . Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010; 42(5):410-4. DOI: 10.1038/ng.569. View

Huo X, Lu C, Huang X, Hu Z, Jin G, Ma H . Polymorphisms in BRCA1, BRCA1-interacting genes and susceptibility of breast cancer in Chinese women. J Cancer Res Clin Oncol. 2009; 135(11):1569-75. DOI: 10.1007/s00432-009-0604-6. View

Tan W, Kim S, Boyer T . Tetrameric oligomerization mediates transcriptional repression by the BRCA1-dependent Kruppel-associated box-zinc finger protein ZBRK1. J Biol Chem. 2004; 279(53):55153-60. DOI: 10.1074/jbc.M410926200. View

Furuta S, Wang J, Wei S, Jeng Y, Jiang X, Gu B . Removal of BRCA1/CtIP/ZBRK1 repressor complex on ANG1 promoter leads to accelerated mammary tumor growth contributed by prominent vasculature. Cancer Cell. 2006; 10(1):13-24. DOI: 10.1016/j.ccr.2006.05.022. View

Cao L, Xu X, Bunting S, Liu J, Wang R, Cao L . A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol Cell. 2009; 35(4):534-41. PMC: 3392030. DOI: 10.1016/j.molcel.2009.06.037. View

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Garcia-Closas M, Egan K, Newcomb P, Brinton L, Titus-Ernstoff L, Chanock S . Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet. 2006; 119(4):376-88. DOI: 10.1007/s00439-006-0135-z. View

Duval S, Tweedie R . Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56(2):455-63. DOI: 10.1111/j.0006-341x.2000.00455.x. View

10.

Antoniou A, Pharoah P, Smith P, Easton D . The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer. 2004; 91(8):1580-90. PMC: 2409934. DOI: 10.1038/sj.bjc.6602175. View

11.

Miki Y, Swensen J, Futreal P, Harshman K, Tavtigian S, Liu Q . A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266(5182):66-71. DOI: 10.1126/science.7545954. View

12.

Turnbull C, Rahman N . Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet. 2008; 9:321-45. DOI: 10.1146/annurev.genom.9.081307.164339. View

13.

Garcia V, Dominguez G, Garcia J, Silva J, Pena C, Silva J . Altered expression of the ZBRK1 gene in human breast carcinomas. J Pathol. 2004; 202(2):224-32. DOI: 10.1002/path.1513. View

14.

Chen Y, Farmer A, Chen C, Jones D, Chen P, Lee W . BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res. 1996; 56(14):3168-72. View

15.

Garcia V, Garcia J, Pena C, Silva J, Dominguez G, Rodriguez R . The GADD45, ZBRK1 and BRCA1 pathway: quantitative analysis of mRNA expression in colon carcinomas. J Pathol. 2005; 206(1):92-9. DOI: 10.1002/path.1751. View

16.

Shibuya K, Mathers C, Boschi-Pinto C, Lopez A, Murray C . Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer. 2002; 2:37. PMC: 149364. DOI: 10.1186/1471-2407-2-37. View

17.

Wooster R, Weber B . Breast and ovarian cancer. N Engl J Med. 2003; 348(23):2339-47. DOI: 10.1056/NEJMra012284. View

18.

Antoniou A, Pharoah P, McMullan G, Day N, Ponder B, Easton D . Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol. 2001; 21(1):1-18. DOI: 10.1002/gepi.1014. View

19.

Fan W, Jin S, Tong T, Zhao H, Fan F, Antinore M . BRCA1 regulates GADD45 through its interactions with the OCT-1 and CAAT motifs. J Biol Chem. 2002; 277(10):8061-7. DOI: 10.1074/jbc.M110225200. View

20.

Couch F, DeShano M, Blackwood M, Calzone K, Stopfer J, Campeau L . BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997; 336(20):1409-15. DOI: 10.1056/NEJM199705153362002. View